Newspaper publication inrespect of opening of special window for transfer and dematerialisation of shares
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals has published a notice in the Navhind Times (dated February 7, 2026) informing shareholders about a SEBI-mandated special window for transferring and dematerialising physical securities. The window is open from February 5, 2026 to February 4, 2027, as per SEBI Circular dated January 30, 2026. Shares transferred under this window will be credited only in demat form to the transferee's account and will carry a 1-year lock-in during which they cannot be transferred, lien-marked, or pledged. The notice also covers earlier transfer requests that were rejected, returned, or pending. Eligible shareholders are asked to submit original share certificates and documents to the company's RTA, MUFG Intime India Private Limited, in Mumbai. The same newspaper page also carries an extract of Q3 FY26 (quarter ended December 31, 2025) standalone unaudited results, approved by the board on February 6, 2026.
This is a routine investor communication and regulatory compliance filing, with no direct impact on the stock price. Shareholders holding physical share certificates now have a fresh one-year opportunity to convert them into demat form. Separately, Q3 FY26 net profit after tax rose to ₹97.51 lakhs from ₹52.43 lakhs in the previous quarter and ₹55.55 lakhs in Q3 FY25, with EPS at ₹1.01 versus ₹0.57 a year earlier, indicating year-on-year profit growth.